Search News
| 83.04 Delayed Data As of Aug 17 |  +0.85 / +1.03%Today’s Change | 72.30 Today|||52-Week Range 94.19 | -1.10% Year-to-Date |
| Merck, Eisai Get FDA Approval for Lenvima Label Expansion Aug 17 / Zacks.com - Paid Partner Content | Ligand (LGND) Beats on Q2 Earnings & Revenues, Raises View Aug 07 / Zacks.com - Paid Partner Content |
| Regeneron's 12-Week Eylea Dose Gets CRL From FDA for Wet AMD Aug 14 / Zacks.com - Paid Partner Content | The Zacks Analyst Blog Highlights: Pfizer, Bristol-Myers, Sanofi, Glaxo and Novartis Aug 06 / Zacks.com - Paid Partner Content |
| Here's Why Lilly (LLY) Stock is Up 15% Since Q2 Earnings Aug 13 / Zacks.com - Paid Partner Content | Sanofi and Novartis are stockpiling drugs to prepare for Brexit Aug 01 / CNNMoney.com |
| Roche's (RHHBY) Xolair Gets Breakthrough Therapy Status Aug 13 / Zacks.com - Paid Partner Content | Trump vs. the Fed; GE earnings; Skechers slump Jul 20 / CNNMoney.com |
| Previous close | 82.19 |
| Today’s open | 82.79 |
| Day’s range | 82.75 - 83.22 |
| Volume | 1,361,855 |
| Average volume (3 months) | 1,809,264 |
| Market cap | $190.0B |
| Earnings growth (last year) | +17.07% |
| Earnings growth (this year) | +9.46% |
| Earnings growth (next 5 years) | +6.41% |
| Revenue growth (last year) | +1.88% |
| P/E ratio | 14.1 |
| Price/Sales | 4.03 |
| Price/Book | 2.56 |
| Today’s change | Today’s % change | |
|---|---|---|
| PFEPfizer | +0.67 | +1.62% |
| MRKMerck | +0.21 | +0.31% |
| SNYSanofi | +0.79 | +1.92% |
| ABBVAbbVie | +0.59 | +0.60% |
| Next reporting date | October 18, 2018 |
| EPS forecast (this quarter) | $1.30 |
| Annual revenue (last year) | $49.4B |
| Annual profit (last year) | $7.7B |
| Net profit margin | 15.69% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
Chief Executive Officer Vasant Narasimhan |
Chief Financial Officer Harry Werner Kirsch |
Corporate headquarters Basel, Basel-stadt (basle Town) |
